Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy

This study analyzes the genes of lung cancer patients who received immunotherapy (checkpoint inhibitor drugs) to find biological markers that can predict who is most likely to benefit from this type of treatment. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with lung cancer confirmed by biopsy - You have been treated with immune checkpoint inhibitor therapy (such as pembrolizumab, nivolumab, or atezolizumab) **You may NOT be eligible if...** - There are no stated exclusion criteria for this study — if you meet all three inclusion criteria above, you are generally eligible Talk to your doctor to see if this trial is right for you.